A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Lymphoma, Non-Hodgkin
  • Receptors, TNF-Related Apoptosis-Inducing Ligand

abstract

  • mapatumumab is safe and has promising clinical activity in patients with FL.

publication date

  • December 7, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3008610

Digital Object Identifier (DOI)

  • 10.1038/sj.bjc.6605987

PubMed ID

  • 21081929

Additional Document Info

start page

  • 1783

end page

  • 7

volume

  • 103

number

  • 12